Literature DB >> 34942142

The neuropsychiatry of Parkinson's disease: advances and challenges.

Daniel Weintraub1, Dag Aarsland2, Kallol Ray Chaudhuri3, Roseanne D Dobkin4, Albert Fg Leentjens5, Mayela Rodriguez-Violante6, Anette Schrag7.   

Abstract

In people with Parkinson's disease, neuropsychiatric signs and symptoms are common throughout the disease course. These symptoms can be disabling and as clinically relevant as motor symptoms, and their presentation can be similar to, or distinct from, their counterparts in the general population. Correlates and risk factors for developing neuropsychiatric signs and symptoms include demographic, clinical, and psychosocial characteristics. The underlying neurobiology of these presentations is complex and not well understood, with the strongest evidence for neuropathological changes associated with Parkinson's disease, mechanisms linked to dopaminergic therapy, and effects not specific to Parkinson's disease. Assessment instruments and formal diagnostic criteria exist, but there is little routine screening of these signs and symptoms in clinical practice. Mounting evidence supports a range of pharmacological and non-pharmacological interventions, but relatively few efficacious treatment options exist. Optimising the management of neuropsychiatric presentations in people with Parkinson's disease will require additional research, raised awareness, specialised training, and development of innovative models of care.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 34942142      PMCID: PMC8800169          DOI: 10.1016/S1474-4422(21)00330-6

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  116 in total

Review 1.  Apathy in Parkinson's disease: A systematic review and meta-analysis.

Authors:  Melina G H E den Brok; Jan Willem van Dalen; Willem A van Gool; Eric P Moll van Charante; Rob M A de Bie; Edo Richard
Journal:  Mov Disord       Date:  2015-03-18       Impact factor: 10.338

2.  Dopamine metabolism of the nucleus accumbens and fronto-striatal connectivity modulate impulse control.

Authors:  Jochen Hammes; Hendrik Theis; Kathrin Giehl; Merle C Hoenig; Andrea Greuel; Marc Tittgemeyer; Lars Timmermann; Gereon R Fink; Alexander Drzezga; Carsten Eggers; Thilo van Eimeren
Journal:  Brain       Date:  2019-03-01       Impact factor: 13.501

3.  Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease.

Authors:  Daniel Weintraub; Claire Chiang; Hyungjin Myra Kim; Jayne Wilkinson; Connie Marras; Barbara Stanislawski; Eugenia Mamikonyan; Helen C Kales
Journal:  JAMA Neurol       Date:  2016-05-01       Impact factor: 18.302

4.  Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease.

Authors:  Kara M Smith; Sharon X Xie; Daniel Weintraub
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-11-03       Impact factor: 10.154

5.  Left Prefrontal Connectivity Links Subthalamic Stimulation with Depressive Symptoms.

Authors:  Friederike Irmen; Andreas Horn; Philip Mosley; Alistair Perry; Jan Niklas Petry-Schmelzer; Haidar S Dafsari; Michael Barbe; Veerle Visser-Vandewalle; Gerd-Helge Schneider; Ningfei Li; Dorothee Kübler; Gregor Wenzel; Andrea A Kühn
Journal:  Ann Neurol       Date:  2020-04-30       Impact factor: 10.422

Review 6.  Medications, Deep Brain Stimulation, and Other Factors Influencing Impulse Control Disorders in Parkinson's Disease.

Authors:  Robert S Eisinger; Adolfo Ramirez-Zamora; Samuel Carbunaru; Brandon Ptak; Zhongxing Peng-Chen; Michael S Okun; Aysegul Gunduz
Journal:  Front Neurol       Date:  2019-02-26       Impact factor: 4.003

Review 7.  Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.

Authors:  Klaus Seppi; K Ray Chaudhuri; Miguel Coelho; Susan H Fox; Regina Katzenschlager; Santiago Perez Lloret; Daniel Weintraub; Cristina Sampaio
Journal:  Mov Disord       Date:  2019-01-17       Impact factor: 10.338

8.  Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease.

Authors:  Robert A Hauser; Jaroslaw Slawek; Paolo Barone; Elisabeth Dohin; Erwin Surmann; Mahnaz Asgharnejad; Lars Bauer
Journal:  BMC Neurol       Date:  2016-06-07       Impact factor: 2.474

Review 9.  Brain mechanisms underlying apathy.

Authors:  Campbell Le Heron; Clay B Holroyd; John Salamone; Masud Husain
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-10-26       Impact factor: 10.154

10.  Differences in network controllability and regional gene expression underlie hallucinations in Parkinson's disease.

Authors:  Angeliki Zarkali; Peter McColgan; Mina Ryten; Regina Reynolds; Louise-Ann Leyland; Andrew J Lees; Geraint Rees; Rimona S Weil
Journal:  Brain       Date:  2020-12-05       Impact factor: 13.501

View more
  12 in total

Review 1.  Randomized controlled trials on the use of cannabis-based medicines in movement disorders: a systematic review.

Authors:  P Oikonomou; W H Jost
Journal:  J Neural Transm (Vienna)       Date:  2022-07-20       Impact factor: 3.850

Review 2.  Central and Peripheral Inflammation: Connecting the Immune Responses of Parkinson's Disease.

Authors:  Gregory P Williams; Aubrey M Schonhoff; Alessandro Sette; Cecilia S Lindestam Arlehamn
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 3.  Psychological outcomes of the COVID-19 pandemic in patients with Parkinson's disease: A systematic review.

Authors:  Fardin Nabizadeh; Zahrasadat Seyedalhosseini; Mohammad Balabandian; Mohammad Reza Rostami
Journal:  J Clin Neurosci       Date:  2022-06-28       Impact factor: 2.116

Review 4.  Psychosis in Parkinson's Disease: A Lesson from Genetics.

Authors:  Efthalia Angelopoulou; Anastasia Bougea; Sokratis G Papageorgiou; Chiara Villa
Journal:  Genes (Basel)       Date:  2022-06-20       Impact factor: 4.141

5.  The relationship between meaning in life and apathy in people with Parkinson's disease: a cross-sectional analysis.

Authors:  Bradley McDaniels; Beatrice Lee; Stuart Rumrill; Kirsteen Edereka-Great; Indu Subramanian
Journal:  Aging Clin Exp Res       Date:  2022-10-21       Impact factor: 4.481

Review 6.  The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease.

Authors:  Akihisa Mori; Jiang-Fan Chen; Shinichi Uchida; Cecile Durlach; Shelby M King; Peter Jenner
Journal:  Molecules       Date:  2022-04-06       Impact factor: 4.411

7.  Pitx3 deficiency promotes age-dependent alterations in striatal medium spiny neurons.

Authors:  Xi Chen; Zhaofei Yang; Yaping Shao; Kunhyok Kim; Yuanyuan Wang; Ying Wang; Haifeng Wu; Xiaolan Xu; Weidong Le
Journal:  Front Aging Neurosci       Date:  2022-09-07       Impact factor: 5.702

8.  Repeating patterns: Predictive processing suggests an aesthetic learning role of the basal ganglia in repetitive stereotyped behaviors.

Authors:  Blanca T M Spee; Ronald Sladky; Joerg Fingerhut; Alice Laciny; Christoph Kraus; Sidney Carls-Diamante; Christof Brücke; Matthew Pelowski; Marco Treven
Journal:  Front Psychol       Date:  2022-09-08

9.  Spiritual Dimension in Neurological and Neurodegenerative Diseases: A Systematic Mapping Review.

Authors:  Rocío de Diego-Cordero; Irene Martos-Lorite; Juan Vega-Escaño
Journal:  J Relig Health       Date:  2022-10-15

10.  Single-nucleus RNA sequencing reveals the shared mechanisms inducing cognitive impairment between COVID-19 and Alzheimer's disease.

Authors:  Yifan Fu; Zhirong Guo; Yulin Wang; Haonan Zhang; Feifan Zhang; Zihao Xu; Xin Shen; Reiko T Roppongi; Shaocong Mo; Wenchao Gu; Takahito Nakajima; Yoshito Tsushima
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.